News

First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months Expected by Year-End 2025 Strengthened Leadership Team with the Appointment of Tony Gibney as Chief Financial and Business Officer BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors…

BOSTON, May 15, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, to certain investors, pre-funded warrants…

2025-06-05 We are pleased to announce that the results from the positive 24w NEXUS interim analysis conducted in 2023 have been published in a manuscript entitled “Safety and efficacy of leriglitazone in childhood cerebral adrenoleukodystrophy (NEXUS): an interim analysis of an open-label, phase 2/3 trial” in eClinicalMedicine, part of THE LANCET DiscoveryScience (https://doi.org/10.1016/j.eclinm.2025.103265). We would…

GLM101 is the first disease-modifying therapeutic in development to treat PMM2-CDG, the most common congenital disorder of glycosylation Data from the ongoing Phase 2 open-label study of GLM101 provide clinical proof of concept, showing improvement in ataxia, a key burden of disease in PMM2-CDG Funding will support advancement of GLM101 into a randomized, placebo-controlled Phase…